[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20121363A1 - Antagonistas de il-17a - Google Patents

Antagonistas de il-17a

Info

Publication number
PE20121363A1
PE20121363A1 PE2012000591A PE2012000591A PE20121363A1 PE 20121363 A1 PE20121363 A1 PE 20121363A1 PE 2012000591 A PE2012000591 A PE 2012000591A PE 2012000591 A PE2012000591 A PE 2012000591A PE 20121363 A1 PE20121363 A1 PE 20121363A1
Authority
PE
Peru
Prior art keywords
human
residue
interact
seq
amino acid
Prior art date
Application number
PE2012000591A
Other languages
English (en)
Inventor
Merle Elloso
Jinquan Luo
Michael Naso
Raymond Sweet
Sheng-Jiun Wu
Daniela Della Ducata
Robert Rauchenberger
Mark Rutz
Juan Carlos Almagro
Susann Taudte
Biugyuan Wu
Galina Obmolova
Thomas Malia
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121363(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20121363A1 publication Critical patent/PE20121363A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

REFERIDA A UN ANTICUERPO AISLADO O FRAGMENTO DE ESTE QUE SE UNE ESPECIFICAMENTE A IL-17A HUMANA Y QUE TIENE UNA SEC ID NO:105 EN LOS RESIDUOS DE AMINOACIDOS 56-68 (SEC ID NO:157) Y 100-116 (SEC ID NO:158) O EN LOS RESIDUOS L26, R55, E57, P59, E60, R61, Y62, S64, V65, W67, R101, E102, P103 Y F110. DICHO ANTICUERPO COMPRENDE RESIDUOS DE AMINOACIDOS DE CADENA PESADA DE PARATOPO DE REGION VARIABLE QUE INTERACTUAN CON RESIDUOS DE IL-17A HUMANA QUE TIENE LA SECUENCIA DE AMINOACIDOS MOSTRADA EN LA SEC ID NO:105 QUE COMPRENDE: a) UN PRIMER RESIDUO DE TREONINA QUE INTERACTUA CON R55 O E57 DE IL-17A HUMANA, b) UN RESIDUO DE GLUTAMINA QUE INTERACTUA CON R55 O E57 DE IL-17A HUMANA, c) UN RESIDUO DE LISINA QUE INTERACTUA CON E57 DE IL-17A HUMANA, d) UN RESIDUO DE TIROSINA QUE INTERACTUA CON P59, E60 O R101 DE IL-17A HUMANA, e) UN RESIDUO DE FENILALANINA QUE INTERACTUA CON E60 DE IL-17A HUMANA Y g) UN SEGUNDO RESIDUO DE TREONINA QUE INTERACTUA CON E60 DE IL-17A HUMANA. TAMBIEN ESTA REFERIDA A UN POLINUCLEOTIDO, UN VECTOR Y UNA CELULA HUESPED
PE2012000591A 2009-10-30 2010-10-29 Antagonistas de il-17a PE20121363A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25686209P 2009-10-30 2009-10-30
US31091910P 2010-03-05 2010-03-05

Publications (1)

Publication Number Publication Date
PE20121363A1 true PE20121363A1 (es) 2012-10-15

Family

ID=43922991

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012000591A PE20121363A1 (es) 2009-10-30 2010-10-29 Antagonistas de il-17a

Country Status (22)

Country Link
US (1) US8519107B2 (es)
EP (1) EP2493506B1 (es)
JP (1) JP5922025B2 (es)
KR (1) KR101836217B1 (es)
CN (1) CN102905727B (es)
AU (1) AU2010313304B2 (es)
BR (1) BR112012010280B1 (es)
CA (1) CA2779257C (es)
CL (1) CL2012001141A1 (es)
CO (1) CO6541541A2 (es)
CR (1) CR20120298A (es)
EA (1) EA029283B1 (es)
EC (1) ECSP12011871A (es)
ES (1) ES2728115T3 (es)
GT (1) GT201200132A (es)
IL (1) IL219390B (es)
MX (1) MX2012005086A (es)
NI (1) NI201200080A (es)
NZ (1) NZ599737A (es)
PE (1) PE20121363A1 (es)
PH (1) PH12012500862B1 (es)
WO (1) WO2011053763A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
WO2014001368A1 (en) * 2012-06-25 2014-01-03 Orega Biotech Il-17 antagonist antibodies
SG11201505330QA (en) * 2013-02-08 2015-08-28 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
KR102278487B1 (ko) * 2013-11-18 2021-07-19 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 Ｉｌ-17ａ 접합체 및 이의 용도
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
WO2015191583A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US10758526B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
WO2015191568A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
WO2015191617A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
US10799584B2 (en) 2014-06-09 2020-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
WO2015191596A1 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
WO2015191602A2 (en) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
RU2017122172A (ru) * 2014-12-15 2019-01-17 МорфоСис АГ Антитела к IL-17C
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
HK1245882A1 (zh) 2015-01-28 2018-08-31 F. Hoffmann-La Roche Ag 多發性硬化的基因表達標志和治療
CN105315371B (zh) * 2015-03-05 2018-05-29 北京百特美博生物科技有限公司 抗人il-17单克隆抗体
CN106336459B (zh) * 2015-07-13 2020-12-08 三生国健药业（上海）股份有限公司 抗人白细胞介素-17a单克隆抗体、其制备方法和应用
WO2017132457A1 (en) * 2016-01-28 2017-08-03 Janssen Biotech, Inc. BISPECIFIC ANTI-TNF-α/IL-17A ANTIBODIES AND ANTI-TNF-α ANTIBODIES AND METHODS OF THEIR USE
KR102466763B1 (ko) * 2016-04-13 2022-11-11 오리맵스 리미티드 항- psma 항체 및 이의 용도
EA201990673A1 (ru) 2016-09-14 2019-08-30 Бэйцзин Ханми Фарм. Ко., Лтд. Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
CN112203685A (zh) * 2018-03-29 2021-01-08 瑞美德生物医药科技有限公司 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗
WO2019218298A1 (zh) 2018-05-17 2019-11-21 江苏荃信生物医药有限公司 抗人白介素17a单克隆抗体及其应用
CN111303283A (zh) * 2018-12-12 2020-06-19 上海君实生物医药科技股份有限公司 抗il-17a抗体及其应用
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CN114127108A (zh) * 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
WO2021067195A1 (en) 2019-09-30 2021-04-08 Janssen Biotech, Inc. Compositions and methods for an il-17 target engagement assay with large molecule modulators
CN114981660A (zh) 2019-09-30 2022-08-30 詹森药业有限公司 用于具有小分子调节剂的il-17靶向接合测定的组合物和方法
IT202200016722A1 (it) * 2022-08-04 2024-02-04 Paolo Grieco Nuovo peptide derivato da interleuchina-17A (IL-17A) e anticorpo neutralizzante (Ab17-IPL-1)

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU1458500A (en) * 1998-10-30 2000-05-22 Jonathan L. Miller Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein IB alpha
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20050208558A1 (en) * 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
US7091323B2 (en) * 2001-04-24 2006-08-15 Bayer Corporation Human TIMP-1 antibodies
AU2002329540A1 (en) * 2001-06-20 2003-01-02 Morphosys Ag Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US6649055B1 (en) 2002-05-07 2003-11-18 The United States Of America As Represented By The United States Department Of Energy Pump station for radioactive waste water
US20050150002A1 (en) * 2004-01-02 2005-07-07 Dellapenna Dean Novel carotenoid hydroxylases for use in engineering carotenoid metabolism in plants
TW200539855A (en) * 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
AU2005241020B2 (en) 2004-05-03 2008-07-10 Merck Sharp & Dohme Corp. Use of IL-17 expression to predict skin inflammation; methods of treatment
EP1765083A4 (en) 2004-05-28 2008-08-20 Serono Lab USE OF IL-17 TO TREAT FERTILITY DISORDERS
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
LT2481753T (lt) 2005-12-13 2018-05-25 Eli Lilly And Company Anti-il-17 antikūnai
SG10201505755YA (en) * 2005-12-29 2015-09-29 Centocor Inc Human anti-il-23 antibodies, compositions, methods and uses
AU2007226627B2 (en) * 2006-03-10 2012-09-20 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
MX2009001620A (es) 2006-08-11 2009-02-23 Schering Corp Anticuerpos para il-17a.
WO2009003096A2 (en) 2007-06-26 2008-12-31 Centocor, Inc. Il-17 mutein proteins, antibodies, compositions, methods and uses
PE20091234A1 (es) 2007-11-30 2009-09-07 Glaxo Group Ltd Construcciones de union de antigenos
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
JP2011507519A (ja) * 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
EP2347038A4 (en) 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES

Also Published As

Publication number Publication date
KR101836217B1 (ko) 2018-03-08
PH12012500862B1 (en) 2018-10-05
CR20120298A (es) 2014-01-09
CO6541541A2 (es) 2012-10-16
ECSP12011871A (es) 2012-08-31
EA029283B1 (ru) 2018-03-30
ES2728115T3 (es) 2019-10-22
KR20120102662A (ko) 2012-09-18
CN102905727A (zh) 2013-01-30
WO2011053763A3 (en) 2011-10-06
WO2011053763A2 (en) 2011-05-05
IL219390B (en) 2019-01-31
CA2779257C (en) 2019-03-12
AU2010313304A1 (en) 2012-05-24
EP2493506A4 (en) 2013-11-20
NI201200080A (es) 2013-04-22
NZ599737A (en) 2015-02-27
BR112012010280B1 (pt) 2020-09-24
AU2010313304B2 (en) 2015-08-20
IL219390A0 (en) 2012-06-28
GT201200132A (es) 2014-01-17
CA2779257A1 (en) 2011-05-05
JP5922025B2 (ja) 2016-05-25
US8519107B2 (en) 2013-08-27
EP2493506B1 (en) 2019-04-10
US20110236390A1 (en) 2011-09-29
JP2013509193A (ja) 2013-03-14
BR112012010280A2 (pt) 2017-06-20
EA201290254A1 (ru) 2012-12-28
CL2012001141A1 (es) 2012-11-30
EP2493506A2 (en) 2012-09-05
PH12012500862A1 (en) 2018-06-26
MX2012005086A (es) 2012-09-28
CN102905727B (zh) 2016-12-07

Similar Documents

Publication Publication Date Title
PE20121363A1 (es) Antagonistas de il-17a
MX2007010349A (es) Composiciones y metodos para clasificar muestras biologicas.
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
RU2013110576A (ru) Молекулы, связывающиеся с 4-1вв
AR113225A2 (es) Anticuerpo monoclonal aislado que se une específicamente a cxcr4 humano expresado sobre la superficie de una célula y que es capaz de inducir apoptosis de célula tumorales cxcr4⁺ in vivo
CO6190543A2 (es) Anticuerpos anti-factor d humanizados
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
ES2531288T3 (es) Proteína de fusión anticancerígena
RS52713B (en) MONGLONAL ANTIBODIES BINDING HGM-CSF AND MEDICAL COMPOSITIONS CONTAINING THE SAME
RS52782B (en) HIGH AFINITY HUMAN ANTIBODIES FOR THE HUMAN IL-4 RECEPTOR
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
RS53042B (en) ANTIBODIES AGAINST ERBB3 AND THEIR USES
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
MX2011008971A (es) Anticuerpos anti-cemx que pueden enlazarse a mlge humana en linfocitos b.
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
AR083747A1 (es) Anticuerpos anti-il-23
PE20081214A1 (es) Anticuerpo especifico prlr y sus usos
WO2014144542A3 (en) Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
PE20120170A1 (es) Variantes de union a anti-albumina de suero mejoradas
EP4296673A3 (en) Peptides and methods for the detection of lyme disease antibodies
WO2012046061A3 (en) Clostridium difficile antigens
CY1118420T1 (el) Αντι-ιδιοτυπικο αντισωμα εναντι ενος αντισωματος εναντι του βητα αμυλοειδους πεπτιδιου

Legal Events

Date Code Title Description
FD Application declared void or lapsed